ATE161171T1 - Schwimmende pulverformige formulierung mit gesteuerter freigabe - Google Patents

Schwimmende pulverformige formulierung mit gesteuerter freigabe

Info

Publication number
ATE161171T1
ATE161171T1 AT92309204T AT92309204T ATE161171T1 AT E161171 T1 ATE161171 T1 AT E161171T1 AT 92309204 T AT92309204 T AT 92309204T AT 92309204 T AT92309204 T AT 92309204T AT E161171 T1 ATE161171 T1 AT E161171T1
Authority
AT
Austria
Prior art keywords
controlled release
powder formulation
release powder
pharmaceutical
weight
Prior art date
Application number
AT92309204T
Other languages
English (en)
Inventor
Andrew Dennis
Peter Timmins
Kevin Lee
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Application granted granted Critical
Publication of ATE161171T1 publication Critical patent/ATE161171T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Slot Machines And Peripheral Devices (AREA)
  • Adjustment And Processing Of Grains (AREA)
  • Disintegrating Or Milling (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
AT92309204T 1991-10-23 1992-10-08 Schwimmende pulverformige formulierung mit gesteuerter freigabe ATE161171T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/781,620 US5169638A (en) 1991-10-23 1991-10-23 Buoyant controlled release powder formulation

Publications (1)

Publication Number Publication Date
ATE161171T1 true ATE161171T1 (de) 1998-01-15

Family

ID=25123359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92309204T ATE161171T1 (de) 1991-10-23 1992-10-08 Schwimmende pulverformige formulierung mit gesteuerter freigabe

Country Status (16)

Country Link
US (1) US5169638A (de)
EP (1) EP0539059B1 (de)
JP (1) JPH05194195A (de)
AT (1) ATE161171T1 (de)
AU (1) AU660193B2 (de)
CA (1) CA2081070C (de)
DE (1) DE69223588T2 (de)
DK (1) DK0539059T3 (de)
ES (1) ES2109986T3 (de)
FI (1) FI108332B (de)
GR (1) GR3026155T3 (de)
HU (1) HU218273B (de)
MX (1) MX9205920A (de)
NO (1) NO304578B1 (de)
NZ (1) NZ244517A (de)
ZA (1) ZA927433B (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
EP0812195B1 (de) * 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Arzneizubereitungen für piperidinalkanolderivate
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
KR100321489B1 (ko) 1996-07-08 2002-10-09 에드워드 멘델 컴파니 인코포레이티드 고용량의불용성약물용서방성매트릭스
US6074669A (en) * 1997-01-20 2000-06-13 Ranbaxy Laboratories Limited Controlled drug delivery system for diltiazem
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
KR100514264B1 (ko) * 1997-08-26 2005-09-15 아벤티스 파마슈티칼스 인크. 피페리디노알칸올-충혈완화제 조합용 제약 조성물
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
EP2332522A3 (de) 1998-03-19 2011-12-07 Bristol-Myers Squibb Company Zweiphasig kontrolliertes Verabreichungssystem für hochlösliche Arzneimittel und verwandtes Verfahren
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6143325A (en) * 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
KR20010075676A (ko) 1998-11-02 2001-08-09 스톤 스티븐 에프. 활성 제제의 제어 수송
US6475493B1 (en) 1999-09-02 2002-11-05 Norstrum Pharmaceuticals, Inc. Controlled release pellet formulation
IL143375A0 (en) * 1999-09-30 2002-04-21 Penwest Pharmaceuticals Co Sustained release matrix systems for highly soluble drugs
DE10014588A1 (de) 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US20060099245A1 (en) * 2000-08-01 2006-05-11 Manoj Kumar Hydrodynamically balancing oral drug delivery system with biphasic release
US20110171296A1 (en) * 2000-10-30 2011-07-14 Biohit Oyj Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine
FI121528B (fi) * 2000-10-30 2010-12-31 Biohit Oyj Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa
WO2002036077A2 (en) 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
BR0205721A (pt) * 2001-07-06 2003-09-30 Endo Pharmaceuticals Inc Formulações de oximorfona de liberação controlada
US20030060422A1 (en) 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
AU2002348105A1 (en) * 2001-10-29 2003-05-12 King Pharmaceuticals Research And Development, Inc Oral dosage forms for improving the bioavailability of therapeutic agents
US20030152621A1 (en) * 2001-11-21 2003-08-14 Egberink J. G. J. Pharmaceutical formulation of gepirone for oral administration
US7022342B2 (en) 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
WO2003086353A1 (en) * 2002-04-05 2003-10-23 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
US7485322B2 (en) * 2002-12-24 2009-02-03 Lek Pharmaceuticals D.D. Modified release pharmaceutical composition
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
CA2512786A1 (en) * 2003-01-14 2004-08-05 Alza Corporation Methods and dosage forms with modified viscosity layers
EP1592410B1 (de) * 2003-02-11 2008-07-23 Alza Corporation Verfahren und dosierformen mit modifizierter schichtgeometrie
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
ATE454138T1 (de) 2003-08-08 2010-01-15 Biovail Lab Int Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
CA2553381C (en) 2004-01-20 2011-03-22 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
JP2007522203A (ja) * 2004-02-11 2007-08-09 アスファーマ・リミテッド 時間療法用組成物とそれらの使用方法
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US20060105044A1 (en) 2004-05-20 2006-05-18 Singh Bramah N Sustained release formulations of sotalol
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
US20070178155A1 (en) * 2006-01-31 2007-08-02 Jiang David Yihai Preparation for gastric buoyant sustained drug release dosage form
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
EP2133071A1 (de) * 2008-06-09 2009-12-16 Université de la Méditerranée Verfahren zur Herstellung gastroretentiver Darreichungsformen
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
JP5982287B2 (ja) 2009-11-09 2016-08-31 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 発毛を刺激する組成物および方法
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
SI2739270T1 (sl) * 2011-08-01 2020-10-30 Hb Biotechnologies Corporation Neprebavljive kapsule za dostavo materialov, ki absorbirajo tekočino
WO2013140222A1 (en) * 2012-03-23 2013-09-26 Pharma73, S.A. Natural biocomposite powder prepared from pichia pastoris biomass, method of preparation and its use as excipient
RU2641021C2 (ru) 2013-02-15 2018-01-17 Аллерган, Инк. Имплантат для пролонгированной доставки лекарственного средства
WO2014188266A1 (en) 2013-05-24 2014-11-27 Rhodes Technologies Opioid ketal compounds and uses thereof
SG10201810255YA (en) 2014-05-21 2018-12-28 Pharma73 S A Chitin-glucan complex, its preparation, and uses
US11845759B2 (en) 2018-02-23 2023-12-19 Rhodes Technologies Opioid compounds and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4101650A (en) * 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
JPH0764737B2 (ja) * 1984-04-19 1995-07-12 ローヌ−プーラン ローラー インターナショナル （ホウルディングス） インコーポレイテッド 制酸組成物
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
DK162986A (da) * 1985-04-12 1986-10-13 Forest Laboratories Terapeutisk middel i enhedsdosisform
US4814178A (en) * 1987-07-01 1989-03-21 Sanford Bolton Floating sustained release therapeutic compositions
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
AU627775B2 (en) * 1988-09-20 1992-09-03 Glaxo Group Limited Pharmaceutical compositions

Also Published As

Publication number Publication date
DK0539059T3 (da) 1998-01-26
ES2109986T3 (es) 1998-02-01
MX9205920A (es) 1993-06-01
GR3026155T3 (en) 1998-05-29
ZA927433B (en) 1993-04-07
DE69223588D1 (de) 1998-01-29
AU2716792A (en) 1993-04-29
CA2081070A1 (en) 1993-04-24
NZ244517A (en) 1994-10-26
NO304578B1 (no) 1999-01-18
EP0539059A1 (de) 1993-04-28
HUT63325A (en) 1993-08-30
CA2081070C (en) 2002-12-24
HU9203342D0 (en) 1992-12-28
AU660193B2 (en) 1995-06-15
FI924831A0 (fi) 1992-10-23
US5169638A (en) 1992-12-08
JPH05194195A (ja) 1993-08-03
FI924831A (fi) 1993-04-24
HU218273B (en) 2000-07-28
NO924104D0 (no) 1992-10-22
DE69223588T2 (de) 1998-06-25
EP0539059B1 (de) 1997-12-17
FI108332B (fi) 2002-01-15
NO924104L (no) 1993-04-26

Similar Documents

Publication Publication Date Title
ATE161171T1 (de) Schwimmende pulverformige formulierung mit gesteuerter freigabe
DE3750145D1 (de) Zusammensetzung mit kontrollierter Freisetzung von Dihydrocodein.
CA1217423A (en) Soft capsules
ZA878601B (en) Spheroids
DK74187D0 (da) Praeparat til langsom frigivelse samt fremgangsmaade til fremstilling deraf
ATE67933T1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
GB1533283A (en) Mixtures for anchoring bone implants
KR890011609A (ko) 구충 분열체를 사용한 포자충증에 대한 생백신
ATE5852T1 (de) Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung.
ES510245A0 (es) "un metodo para obtener una preparacion de insulina".
JPS6479109A (en) Floating continuous release therapy composition
JPS5724634A (en) Deoxydizer composition
FR2649710B1 (de)
JPS5553215A (en) Hydrosol or gel of polyanion polymer, its preparation, and preparation of enteric drug using the same
EP0416722A3 (en) Pharmaceutical compositions having differential drug release rate
EP1046345A3 (de) Zubereitung zur Verabreichung an Tiere und Fütterungsverfahren
JPS5534058A (en) Immobilization of bioactive substance to powdery carrier

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee